NCT04691817RecruitingPhase 1/2
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 28 (estimated)
- First submitted
- 8 Dec 2020
- Start date
- 25 Jul 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Lung cancer
- NCT number
- NCT04691817
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 28
- From 25 Jul 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of a driver mutation that is susceptible to targeted therapy
- No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
Other illness
- Other active invasive malignancy requiring ongoing therapy
- Evidence or history of leptomeningeal disease
- History of an autoimmune disease or IPF
Other
- Evidence of progressing or untreated brain metastases
- Uncontrolled tumor related pain
Who the study is looking for
- Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
- Prior exposure to at least 1 line of therapy
- Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
- ECOG PS 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.